Abstract
Psoriasis is a chronic, systemic inflammatory disease that in the moderate to severe forms may benefit of biologics, namely TNF and IL-12/23 and IL-17 inhibitors. Loss of response, lack of response or discontinuation due to adverse events represent a concrete therapeutic challenge for dermatologists that have to switch patients to other treatments. Although some evidences already exist toward the switch from IL-12/23 and TNF inhibitors to IL-17 inhibitors, conversely nothing is present toward the switch from IL-17 inhibitors to IL-12/23 and TNF inhibitors. We performed a real-life study enrolling 50 patients randomly switched to adalimuamb, a TNF inhibitor, or ustekinumab, an IL-12/23 inhibitor. Our observational study suggests that switching from IL-17i to TNFi and IL-12/23i is a safe and effective therapeutic strategy. This article is protected by copyright. All rights reserved.
| Original language | English |
|---|---|
| Pages (from-to) | e12793 |
| Journal | Dermatologic Therapy |
| DOIs | |
| Publication status | E-pub ahead of print - Dec 5 2018 |
Fingerprint
Cite this
When IL-17 inhibitors fail : real-life evidence to switch from secukinumab to adalimumab or ustekinumab. / Damiani, Giovanni; Conic, Rosalynn Rz; de Vita, Valerio; Costanzo, Antonio; Regazzini, Roberto; Pigatto, Paolo Dm; Bragazzi, Nicola L; Pacifico, Alessia; Malagoli, Piergiorgio.
In: Dermatologic Therapy, 05.12.2018, p. e12793.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - When IL-17 inhibitors fail
T2 - real-life evidence to switch from secukinumab to adalimumab or ustekinumab
AU - Damiani, Giovanni
AU - Conic, Rosalynn Rz
AU - de Vita, Valerio
AU - Costanzo, Antonio
AU - Regazzini, Roberto
AU - Pigatto, Paolo Dm
AU - Bragazzi, Nicola L
AU - Pacifico, Alessia
AU - Malagoli, Piergiorgio
N1 - This article is protected by copyright. All rights reserved.
PY - 2018/12/5
Y1 - 2018/12/5
N2 - Psoriasis is a chronic, systemic inflammatory disease that in the moderate to severe forms may benefit of biologics, namely TNF and IL-12/23 and IL-17 inhibitors. Loss of response, lack of response or discontinuation due to adverse events represent a concrete therapeutic challenge for dermatologists that have to switch patients to other treatments. Although some evidences already exist toward the switch from IL-12/23 and TNF inhibitors to IL-17 inhibitors, conversely nothing is present toward the switch from IL-17 inhibitors to IL-12/23 and TNF inhibitors. We performed a real-life study enrolling 50 patients randomly switched to adalimuamb, a TNF inhibitor, or ustekinumab, an IL-12/23 inhibitor. Our observational study suggests that switching from IL-17i to TNFi and IL-12/23i is a safe and effective therapeutic strategy. This article is protected by copyright. All rights reserved.
AB - Psoriasis is a chronic, systemic inflammatory disease that in the moderate to severe forms may benefit of biologics, namely TNF and IL-12/23 and IL-17 inhibitors. Loss of response, lack of response or discontinuation due to adverse events represent a concrete therapeutic challenge for dermatologists that have to switch patients to other treatments. Although some evidences already exist toward the switch from IL-12/23 and TNF inhibitors to IL-17 inhibitors, conversely nothing is present toward the switch from IL-17 inhibitors to IL-12/23 and TNF inhibitors. We performed a real-life study enrolling 50 patients randomly switched to adalimuamb, a TNF inhibitor, or ustekinumab, an IL-12/23 inhibitor. Our observational study suggests that switching from IL-17i to TNFi and IL-12/23i is a safe and effective therapeutic strategy. This article is protected by copyright. All rights reserved.
U2 - 10.1111/dth.12793
DO - 10.1111/dth.12793
M3 - Article
SP - e12793
JO - Dermatologic Therapy
JF - Dermatologic Therapy
SN - 1396-0296
ER -